Biogen, Inc. - Product Pipeline Review - 2016

Published: Feb, 2016 | Pages: 94 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Biogen, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Biogen, Inc. - Product Pipeline Review - 2016', provides an overview of the Biogen, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Biogen, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Biogen, Inc.
- The report provides overview of Biogen, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Biogen, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Biogen, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Biogen, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Biogen, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biogen, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Biogen, Inc. Snapshot 7
Biogen, Inc. Overview 7
Key Information 7
Key Facts 7
Biogen, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Biogen, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 16
Out-Licensed Products/Combination Treatment Modalities 17
Biogen, Inc. - Pipeline Products Glance 18
Biogen, Inc. - Late Stage Pipeline Products 18
Pre-Registration Products/Combination Treatment Modalities 18
Phase III Products/Combination Treatment Modalities 19
Biogen, Inc. - Clinical Stage Pipeline Products 20
Phase II Products/Combination Treatment Modalities 20
Phase I Products/Combination Treatment Modalities 21
Biogen, Inc. - Early Stage Pipeline Products 22
Preclinical Products/Combination Treatment Modalities 22
Discovery Products/Combination Treatment Modalities 23
Biogen, Inc. - Drug Profiles 24
coagulation factor IX (recombinant), Fc fusion protein 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
rituximab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
aducanumab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
amiselimod hydrochloride 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BG-00011 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
natalizumab 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
opicinumab 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
raxatrigine hydrochloride 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BG-00001 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BIIB-054 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BIIB-059 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
BIIB-061 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BIIB-063 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
dapirolizumab pegol 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
5-D10 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CNV-1061436 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CNV-3000164 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CNV-3000223 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Gene Therapy for Hemophilia B 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NI-105 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NI-205 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PRT-2761 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Recombinant Protein to Replace Factor VIII for Hemophilia A 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecule to Antagonize GPR-84 for Chronic Pain 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecule to Inhibit mPGES-1 for Chronic Pain 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Small Molecules to Agonize ROR-Gamma for Autoimmune Disease 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Biogen, Inc. - Pipeline Analysis 63
Biogen, Inc. - Pipeline Products by Target 63
Biogen, Inc. - Pipeline Products by Route of Administration 66
Biogen, Inc. - Pipeline Products by Molecule Type 67
Biogen, Inc. - Pipeline Products by Mechanism of Action 68
Biogen, Inc. - Recent Pipeline Updates 70
Biogen, Inc. - Dormant Projects 83
Biogen, Inc. - Discontinued Pipeline Products 85
Discontinued Pipeline Product Profiles 85
baminercept alfa 85
BG-00010 85
BIIB-023 85
clenoliximab 85
CNF-1010 85
dexpramipexole dihydrochloride 86
naxifylline 86
Biogen, Inc. - Company Statement 87
Biogen, Inc. - Locations And Subsidiaries 88
Head Office 88
Other Locations & Subsidiaries 88
Biogen, Inc. - Key Manufacturing Facilities 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94

List of Tables
Biogen, Inc., Key Information 7
Biogen, Inc., Key Facts 7
Biogen, Inc. - Pipeline by Indication, 2016 9
Biogen, Inc. - Pipeline by Stage of Development, 2016 11
Biogen, Inc. - Monotherapy Products in Pipeline, 2016 12
Biogen, Inc. - Partnered Products in Pipeline, 2016 13
Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14
Biogen, Inc. - Out-Licensed Products in Pipeline, 2016 16
Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17
Biogen, Inc. - Pre-Registration, 2016 18
Biogen, Inc. - Phase III, 2016 19
Biogen, Inc. - Phase II, 2016 20
Biogen, Inc. - Phase I, 2016 21
Biogen, Inc. - Preclinical, 2016 22
Biogen, Inc. - Discovery, 2016 23
Biogen, Inc. - Pipeline by Target, 2016 63
Biogen, Inc. - Pipeline by Route of Administration, 2016 66
Biogen, Inc. - Pipeline by Molecule Type, 2016 67
Biogen, Inc. - Pipeline Products by Mechanism of Action, 2016 68
Biogen, Inc. - Recent Pipeline Updates, 2016 70
Biogen, Inc. - Dormant Developmental Projects,2016 83
Biogen, Inc. - Discontinued Pipeline Products, 2016 85
Biogen, Inc., Other Locations 88
Biogen, Inc., Subsidiaries 88
Biogen, Inc., Key Manufacturing Facilities 92